A Phase 2 interventional study of Radiation Therapy and Enzalutamide in Prostate Cancer, sponsored by RTOG Foundation, Inc.. Active, not recruiting at 108 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-30.
Sponsored by RTOG Foundation, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 125 studies testing enzalutamide in Prostatic Neoplasms — 17 open to participants now, 38 under way, 9 of them phase 3. enzalutamide · Prostatic Neoplasms.
Among the 125 studies testing enzalutamide in Prostatic Neoplasms, this one is the 29th largest by enrollment, is one of 7 that started in 2019, is one of 65 in phase 2, reaches primary completion later than 7 of the 37 other live ones, and was the 90th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →17 of the 125 studies testing enzalutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Astellas Pharma Global Development, Inc. · Sites in Bulgaria
Ages 50–75 · Men only · Healthy volunteers
Hyundai Bioscience Co., Ltd. · Sites in Korea, Republic of
Ages 19+ · Men only
University of Michigan Rogel Cancer Center · Sites in United States
Ages 18+ · Men only
Novartis Pharmaceuticals · Sites in United States, Australia, France and 4 more countries
Ages 18+ · Men only
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Men only
By country, each count listing its studies:
enzalutamide: first FDA approval 2012 (XTANDI), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
125 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 33 · Phase 2 78 · Phase 3 18 · Phase 4 7
First in 2005; this study’s year is marked. 7 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 188 is above the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 52 across the 125 interventional studies. Of the 81 that completed or were terminated, 49 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 125 have an industry lead sponsor. The 10 most frequent:
RTOG Foundation, Inc. is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
RTOG Foundation, Inc. has 1 study filed under Prostatic Neoplasms — fewer than ten, so there is no comparison to draw.
13 of the studies testing enzalutamide in Prostatic Neoplasms that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT02446405Phase 3University of SydneyEnzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer | 2026-12-31 |
| NCT05873192M.D. Anderson Cancer CenterPresurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer | 2026-12-31 |
| NCT03344211University of Southern CaliforniaEnzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer | 2026-12-31 |
| NCT05406999The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNeoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer | 2026-12-31 |
Add all 13 to your calendar (.ics) → With an account.
Among the 125 studies testing enzalutamide in Prostatic Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Patients with post-prostatectomy PSA (Prostate Specific Antigen) recurrences with aggressive disease features will receive salvage radiation therapy and standard androgen deprivation therapy (ADT) or enhanced ADT to determine if there is any improvement in progression-free survival when enhanced ADT is used compared to standard ADT.
PRIMARY OBJECTIVE:
To determine whether, in men with post-prostatectomy PSA (prostate specific antigen) recurrences with aggressive disease features, salvage radiotherapy (SRT) with enhanced androgen deprivation therapy (ADT), consisting of enzalutamide (MDV3100) and a GnRH analog, will improve progression-free survival compared to SRT with standard GnRH analog -based ADT.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
At least 1 of the following aggressive features:
Seminal vesicle invasion (SVI) (note any pT stage American Joint Committee on Cancer (AJCC) v8.0 is eligible but a pT stage
≥ pT3b is considered aggressive)
Exclusion Criteria:
History of any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Standard ADT: 24 months of GnRH analog (any formulation) with optional 1-4 months of bicalutamide (50 mg/day). SRT: Starting within 0-70 days of initiation of GnRH analog, 66.6-70.2 Gy as 1.8 Gy/fraction in 37-39 fractions or 66.0-70.0 Gy as 2.0 Gy/fraction in 33-35 fractions lasting approximately 7-8 weeks, and optional lymph node boost.
Radiation: Radiation Therapy · Drug: Bicalutamide · Drug: GnRH analog
Enhanced ADT: 24 months of GnRH analog (any formulation) with 24 months of enzalutamide (160 mg/day). SRT: Starting within 0-70 days of initiation of GnRH analog, 66.6-70.2 Gy as 1.8 Gy/fraction in 37-39 fractions or 66.0-70.0 Gy as 2.0 Gy/fraction in 33-35 fractions lasting approximately 7-8 weeks, and optional lymph node boost.
Radiation: Radiation Therapy · Drug: Enzalutamide · Drug: GnRH analog
daily fractions
Also known as: RT, Image-Guided Radiation Therapy (IGRT), Radiotherapy
tablet
Also known as: Xtandi®
tablet
Also known as: Casodex®
Injection
Also known as: Gonadotropin-releasing hormone analog, Lupron®, leuprolide acetate, goserelin acetate, Eligard™, Viadur™, Zoladex®, Trelstar®
Percentage of Participants Alive Without Progression (Progression-Free Survival)
Progression-free survival (PFS) is estimated by the Kaplan-Meier method. PFS time is measured from randomization to the date of first PFS failure (biochemical or clinical failure, initiation of new unplanned anticancer treatment, or death from any cause) or last known follow-up (censored). Analysis was to occur after progression or death was reported for 101 participants. Biochemical failure is defined as first post-RT detectable PSA (PSA ≥ 0.05). Clinical failure is defined as either a local, regional, or distant failure.
Time frame: From randomization to first failure or last known follow-up. Median follow-up time at the time of analysis was 33.1 months. The 1- and 2-year estimates are reported.
Percentage of Participants With Biochemical Failure
Biochemical failure is defined as the first detectable post-RT prostate-specific antigen (PSA) value (≥ 0.05) or the initiation of salvage hormone therapy. Failure rates are estimated using the cumulative incidence method, treating death as a competing risk, and otherwise censoring participants alive at time of analysis.
Time frame: From randomization to first failure, competing event, or last known follow-up, whichever occurs first. Median follow-up time at the time of analysis was 33.1 months. The 1- and 2-year estimates are reported.
Percentage of Participants With Alternative Biochemical Failure
Alternative biochemical failure is defined as first post-RT PSA ≥ 0.1 ng/mL or initiation of salvage hormone therapy. Failure rates are estimated using the cumulative incidence method, treating death as a competing risk, and otherwise censoring participants alive at time of analysis.
Time frame: From randomization to first failure, competing event, or last known follow-up, whichever occurs first. Median follow-up time at the time of analysis was 33.1 months. The 1- and 2-year estimates are reported.
Percentage of Participants With Hormone-refractory Disease
Hormone-refractory disease is defined as three rises in PSA during salvage androgen deprivation, with the date determined as the midway date between the last non-rising PSA and the first of the three rises. Failure rates were to be estimated using the cumulative incidence method, treating death as a competing risk, and otherwise censoring participants alive at time of analysis, but for endpoints with \< 10 events overall, such as this one, only the counts of participants with the event are provided.
Time frame: From randomization to first failure, competing event, or last known follow-up, whichever occurs first. Median follow-up time at the time of analysis was 33.1 months.
Percentage of Participants With Distant Metastasis
Distant failure is defined as first radiographic evidence of distant metastasis (e.g., bone scan, computed tomography (CT), magnetic resonance imaging (MRI)). Failure rates were to be estimated using the cumulative incidence method, treating death as a competing risk, and otherwise censoring participants alive at time of analysis, but for endpoints with \< 10 events overall, such as this one, only the counts of participants with the event are provided.
Time frame: From randomization to first failure, competing event, or last known follow-up, whichever occurs first. Median follow-up time at the time of analysis was 33.1 months.
Percentage of Participants With Prostate Cancer Death
Cause-specific mortality is defined as death due to prostate cancer. Failure rates were to be estimated using the cumulative incidence method, treating death as a competing risk, and otherwise censoring participants alive at time of analysis, but for endpoints with \< 10 events overall, such as this one, only the counts of participants with the event are provided.
Time frame: From randomization to first failure, competing event, or last known follow-up, whichever occurs first. Median follow-up time at the time of analysis was 33.1 months.
Percentage of Participants Alive (Overall Survival)
Survival rates were to be estimated using the Kaplan-Meier method, censoring participants alive at time of analysis, but for endpoints with \< 10 events overall, such as this one, only counts are provided. In this case, the number of participants without event (death), which is the number of participants alive.
Time frame: From randomization to death or last known follow-up, whichever occurs first. Median follow-up time at the time of analysis was 33.1 months.
Change From Baseline to End of RT in the 5-level European Quality of Life Questionnaire (EQ-5D-5L) Index Score
The EQ-5D-5L is a self-assessment questionnaire. The index score is computed from 5 items (mobility, self care, usual activities, pain/discomfort, anxiety/depression) each with 5 problem levels (1-none to 5-extreme). The 5-item index score is transformed into a utility score between 0 (worst health state) and 1 (best health state). Change score was calculated by subtracting baseline from later score, with a positive change score indicating improvement.
Time frame: Baseline and end of radiation treatment (RT). End of RT can vary greatly depending on when it starts, which can be from 0 to 70 days from the start of ADT, and lasting 7-8 weeks.
Change From Baseline to One Year After End of RT in the EQ-5D-5L Index Score
The EQ-5D-5L is a self-assessment questionnaire. The index score is computed from 5 items (mobility, self care, usual activities, pain/discomfort, anxiety/depression) each with 5 problem levels (1-none to 5-extreme). The 5-item index score is transformed into a utility score between 0 (worst health state) and 1 (best health state). Change score was calculated by subtracting baseline from later score, with a positive change score indicating improvement.
Time frame: Baseline and one year after end RT. End of RT can vary greatly depending on when it starts, which can be from 0 to 70 days from the start of ADT, and lasting 7-8 weeks.
Change From Baseline to Two Years After End of RT in the EQ-5D-5L Index Score
The EQ-5D-5L is a self-assessment questionnaire. The index score is computed from 5 items (mobility, self care, usual activities, pain/discomfort, anxiety/depression) each with 5 problem levels (1-none to 5-extreme). The 5-item index score is transformed into a utility score between 0 (worst health state) and 1 (best health state). Change score was calculated by subtracting baseline from later score, with a positive change score indicating improvement.
Time frame: Baseline and two years after end of RT. End of RT can vary greatly depending on when it starts, which can be from 0 to 70 days from the start of ADT, and lasting 7-8 weeks.
Change From Baseline to End of RT in the 7-item Patient Reported Outcomes Measurement Information System - Fatigue Short Form (PROMIS-F SF 7a) [PROMIS Fatigue Score]
The PROMIS fatigue score measures self-reported fatigue symptoms over the past 7 days. Possible raw scores range from 29.4 to 83.2 (higher raw score indicating greater fatigue) and are converted into standardized T-scores (mean=50, standard deviation=10) with higher scores also indicating greater fatigue. Change score is calculated by subtracting baseline T-score from later T-score, with a positive change score indicating increased fatigue.
Time frame: Baseline and end of RT. End of RT can vary greatly depending on when it starts, which can be from 0 to 70 days from the start of ADT, and lasting 7-8 weeks.
Change From Baseline to One Year After the End of RT in the 7-item Patient Reported Outcomes Measurement Information System - Fatigue Short Form (PROMIS-F SF 7a) [PROMIS Fatigue Score]
The PROMIS fatigue score measures self-reported fatigue symptoms over the past 7 days. Possible raw scores range from 29.4 to 83.2 (higher raw score indicating greater fatigue) and are converted into standardized T-scores (mean=50, standard deviation=10) with higher scores also indicating greater fatigue. Change score is calculated by subtracting baseline T-score from later T-score, with a positive change score indicating increased fatigue.
Time frame: Baseline and one year after end of RT. End of RT can vary greatly depending on when it starts, which can be from 0 to 70 days from the start of ADT, and lasting 7-8 weeks.
Change From Baseline to Two Years After the End of RT in the 7-item Patient Reported Outcomes Measurement Information System - Fatigue Short Form (PROMIS-F SF 7a) [PROMIS Fatigue Score]
The PROMIS fatigue score measures self-reported fatigue symptoms over the past 7 days. Possible raw scores range from 29.4 to 83.2 (higher raw score indicating greater fatigue) and are converted into standardized T-scores (mean=50, standard deviation=10) with higher scores also indicating greater fatigue. Change score is calculated by subtracting baseline T-score from later T-score, with a positive change score indicating increased fatigue.
Time frame: Baseline, two years after end of RT. End of RT can vary greatly depending on when it starts, which can be from 0 to 70 days from the start of ADT, and lasting 7-8 weeks.
Number of Participants by Highest Grade Adverse Event Reported CTCAE v5
Common Terminology Criteria for Adverse Events (version 5) grades adverse event severity as follows: 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, 5 = death related to adverse event. Summary data is provided in this outcome measure; see Adverse Events Module for specific adverse event data.
Time frame: From randomization to death or last known follow-up. Median follow-up time at the time of analysis was 33.1 months.
Number of Participants Any Adverse Event Occuring Within 30 Days Following the End of Treatment
Common Terminology Criteria for Adverse Events (version 5) grades adverse event severity as follows: 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, 5 = death related to adverse event. Summary data is provided in this outcome measure; see Adverse Events Module for specific adverse event data.
Time frame: From randomization to 30 days after the end of RT. End of RT can vary greatly depending on when it starts, which can be from 0 to 70 days from the start of ADT, and lasting 7-8 weeks.
Number of Participants With Any Grade 3+ Adverse Event Occuring After 30 Days Following the End of RT
Common Terminology Criteria for Adverse Events (version 5) grades adverse event severity as follows: 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, 5 = death related to adverse event. Summary data is provided in this outcome measure; see Adverse Events Module for specific adverse event data.
Time frame: From 31 days after the end of RT to death or last known follow-up. Median follow-up was 33.1 months. End of RT can vary greatly depending on when it starts, which can be from 0 to 70 days from the start of ADT, and lasting 7-8 weeks.
Number of Participants With Post-baseline Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Scores ≥ 3
PRO-CTCAE is a patient-reported outcome (PRO) measurement system developed to evaluate symptomatic toxicity in patients on cancer clinical trials, asking the patient about experience over the last seven days. Scores may reflect worst severity of the symptom (0=None, 1=Mild, 2=Moderate, 3=Severe, and 4=Very severe), frequency of the symptom (0=Never, 1=Rarely, 2=Occasionally, 3=Frequently, 4=Almost constantly), or the symptom's interference with one's "usual or daily activities" (0=Not at all, 1=A little bit, 2=Somewhat, 3=Quite a bit, 4=Very much). The symptom row title will indicate "Severity", "Frequency", or "Interference". All scores are compared between arms; statistical analysis results are entered for p-values \< 0.05.
Time frame: End of RT, one and two years after the end of RT. End of RT can vary greatly depending on when it starts, which can be from 0 to 70 days from the start of ADT, and lasting 7-8 weeks.
| Milestone | Salvage Radiation Therapy (SRT) + Standard Androgen Deprivation Therapy (ADT) | Salvage Radiation Therapy + Enhanced ADT |
|---|---|---|
| Started | 98 | 90 |
| Adverse event population | 98 | 89 |
| Completed | 98 | 90 |
| Not completed | 0 | 0 |
Progression-free survival (PFS) is estimated by the Kaplan-Meier method. PFS time is measured from randomization to the date of first PFS failure (biochemical or clinical failure, initiation of new unplanned anticancer treatment, or death from any cause) or last known follow-up (censored). Analysis was to occur after progression or death was reported for 101 participants. Biochemical failure is defined as first post-RT detectable PSA (PSA ≥ 0.05). Clinical failure is defined as either a local, regional, or distant failure.
| percentage of participants | SRT + Standard ADT | SRT + Enhanced ADT |
|---|---|---|
| 1 year | 38.3 (32.0 to 44.7) | 45.5 (38.6 to 52.4) |
| 2 years | 32.1 (26.0 to 38.2) | 38.3 (31.5 to 45.0) |
Biochemical failure is defined as the first detectable post-RT prostate-specific antigen (PSA) value (≥ 0.05) or the initiation of salvage hormone therapy. Failure rates are estimated using the cumulative incidence method, treating death as a competing risk, and otherwise censoring participants alive at time of analysis.
| percentage of participants | SRT + Standard ADT | SRT + Enhanced ADT |
|---|---|---|
| 1 year | 61.7 (51.1 to 70.6) | 54.6 (43.4 to 64.5) |
| 2 years | 67.9 (57.5 to 76.3) | 60.6 (49.3 to 70.2) |
Alternative biochemical failure is defined as first post-RT PSA ≥ 0.1 ng/mL or initiation of salvage hormone therapy. Failure rates are estimated using the cumulative incidence method, treating death as a competing risk, and otherwise censoring participants alive at time of analysis.
| percentage of participants | SRT + Standard ADT | SRT + Enhanced ADT |
|---|---|---|
| 1 year | 35.9 (26.5 to 45.5) | 31.4 (21.9 to 41.3) |
| 2 years | 45.4 (35.2 to 55.0) | 39.9 (29.4 to 50.2) |
Hormone-refractory disease is defined as three rises in PSA during salvage androgen deprivation, with the date determined as the midway date between the last non-rising PSA and the first of the three rises. Failure rates were to be estimated using the cumulative incidence method, treating death as a competing risk, and otherwise censoring participants alive at time of analysis, but for endpoints with \< 10 events overall, such as this one, only the counts of participants with the event are provided.
| Participants | SRT + Standard ADT | SRT + Enhanced ADT |
|---|---|---|
| Percentage of Participants With Hormone-refractory Disease | 0 | 0 |
Distant failure is defined as first radiographic evidence of distant metastasis (e.g., bone scan, computed tomography (CT), magnetic resonance imaging (MRI)). Failure rates were to be estimated using the cumulative incidence method, treating death as a competing risk, and otherwise censoring participants alive at time of analysis, but for endpoints with \< 10 events overall, such as this one, only the counts of participants with the event are provided.
| Participants | SRT + Standard ADT | SRT + Enhanced ADT |
|---|---|---|
| Percentage of Participants With Distant Metastasis | 6 | 1 |
Cause-specific mortality is defined as death due to prostate cancer. Failure rates were to be estimated using the cumulative incidence method, treating death as a competing risk, and otherwise censoring participants alive at time of analysis, but for endpoints with \< 10 events overall, such as this one, only the counts of participants with the event are provided.
| Participants | SRT + Standard ADT | SRT + Enhanced ADT |
|---|---|---|
| Percentage of Participants With Prostate Cancer Death | 0 | 0 |
Survival rates were to be estimated using the Kaplan-Meier method, censoring participants alive at time of analysis, but for endpoints with \< 10 events overall, such as this one, only counts are provided. In this case, the number of participants without event (death), which is the number of participants alive.
| Participants | SRT + Standard ADT | SRT + Enhanced ADT |
|---|---|---|
| Percentage of Participants Alive (Overall Survival) | 96 | 90 |
The EQ-5D-5L is a self-assessment questionnaire. The index score is computed from 5 items (mobility, self care, usual activities, pain/discomfort, anxiety/depression) each with 5 problem levels (1-none to 5-extreme). The 5-item index score is transformed into a utility score between 0 (worst health state) and 1 (best health state). Change score was calculated by subtracting baseline from later score, with a positive change score indicating improvement.
| score on a scale | SRT + Standard ADT | SRT + Enhanced ADT |
|---|---|---|
| Change From Baseline to End of RT in the 5-level European Quality of Life Questionnaire (EQ-5D-5L) Index Score | 0.0 ± 0.1 | 0.0 ± 0.1 |
The EQ-5D-5L is a self-assessment questionnaire. The index score is computed from 5 items (mobility, self care, usual activities, pain/discomfort, anxiety/depression) each with 5 problem levels (1-none to 5-extreme). The 5-item index score is transformed into a utility score between 0 (worst health state) and 1 (best health state). Change score was calculated by subtracting baseline from later score, with a positive change score indicating improvement.
| score on a scale | SRT + Standard ADT | SRT + Enhanced ADT |
|---|---|---|
| Change From Baseline to One Year After End of RT in the EQ-5D-5L Index Score | 0.0 ± 0.1 | 0.0 ± 0.1 |
The EQ-5D-5L is a self-assessment questionnaire. The index score is computed from 5 items (mobility, self care, usual activities, pain/discomfort, anxiety/depression) each with 5 problem levels (1-none to 5-extreme). The 5-item index score is transformed into a utility score between 0 (worst health state) and 1 (best health state). Change score was calculated by subtracting baseline from later score, with a positive change score indicating improvement.
| score on a scale | SRT + Standard ADT | SRT + Enhanced ADT |
|---|---|---|
| Change From Baseline to Two Years After End of RT in the EQ-5D-5L Index Score | 0.0 ± 0.1 | 0.0 ± 0.1 |
The PROMIS fatigue score measures self-reported fatigue symptoms over the past 7 days. Possible raw scores range from 29.4 to 83.2 (higher raw score indicating greater fatigue) and are converted into standardized T-scores (mean=50, standard deviation=10) with higher scores also indicating greater fatigue. Change score is calculated by subtracting baseline T-score from later T-score, with a positive change score indicating increased fatigue.
| score on a scale | SRT + Standard ADT | SRT + Enhanced ADT |
|---|---|---|
| Change From Baseline to End of RT in the 7-item Patient Reported Outcomes Measurement Information System - Fatigue Short Form (PROMIS-F SF 7a) [PROMIS Fatigue Score] | 3.4 ± 7.8 | 6.8 ± 6.4 |
The PROMIS fatigue score measures self-reported fatigue symptoms over the past 7 days. Possible raw scores range from 29.4 to 83.2 (higher raw score indicating greater fatigue) and are converted into standardized T-scores (mean=50, standard deviation=10) with higher scores also indicating greater fatigue. Change score is calculated by subtracting baseline T-score from later T-score, with a positive change score indicating increased fatigue.
| score on a scale | SRT + Standard ADT | SRT + Enhanced ADT |
|---|---|---|
| Change From Baseline to One Year After the End of RT in the 7-item Patient Reported Outcomes Measurement Information System - Fatigue Short Form (PROMIS-F SF 7a) [PROMIS Fatigue Score] | 4.0 ± 7.4 | 7.0 ± 8.0 |
The PROMIS fatigue score measures self-reported fatigue symptoms over the past 7 days. Possible raw scores range from 29.4 to 83.2 (higher raw score indicating greater fatigue) and are converted into standardized T-scores (mean=50, standard deviation=10) with higher scores also indicating greater fatigue. Change score is calculated by subtracting baseline T-score from later T-score, with a positive change score indicating increased fatigue.
| score on a scale | SRT + Standard ADT | SRT + Enhanced ADT |
|---|---|---|
| Change From Baseline to Two Years After the End of RT in the 7-item Patient Reported Outcomes Measurement Information System - Fatigue Short Form (PROMIS-F SF 7a) [PROMIS Fatigue Score] | 4.0 ± 7.5 | 5.0 ± 7.8 |
Common Terminology Criteria for Adverse Events (version 5) grades adverse event severity as follows: 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, 5 = death related to adverse event. Summary data is provided in this outcome measure; see Adverse Events Module for specific adverse event data.
| Participants | SRT + Standard ADT | SRT + Enhanced ADT |
|---|---|---|
| None | 8 | 3 |
| Grade 1 | 19 | 9 |
| Grade 2 | 38 | 32 |
| Grade 3 | 27 | 39 |
| Grade 4 | 6 | 6 |
| Grade 5 | 0 | 0 |
Common Terminology Criteria for Adverse Events (version 5) grades adverse event severity as follows: 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, 5 = death related to adverse event. Summary data is provided in this outcome measure; see Adverse Events Module for specific adverse event data.
| Participants | SRT + Standard ADT | SRT + Enhanced ADT |
|---|---|---|
| Number of Participants Any Adverse Event Occuring Within 30 Days Following the End of Treatment | 86 | 83 |
Common Terminology Criteria for Adverse Events (version 5) grades adverse event severity as follows: 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, 5 = death related to adverse event. Summary data is provided in this outcome measure; see Adverse Events Module for specific adverse event data.
| Participants | SRT + Standard ADT | SRT + Enhanced ADT |
|---|---|---|
| Number of Participants With Any Grade 3+ Adverse Event Occuring After 30 Days Following the End of RT | 27 | 30 |
PRO-CTCAE is a patient-reported outcome (PRO) measurement system developed to evaluate symptomatic toxicity in patients on cancer clinical trials, asking the patient about experience over the last seven days. Scores may reflect worst severity of the symptom (0=None, 1=Mild, 2=Moderate, 3=Severe, and 4=Very severe), frequency of the symptom (0=Never, 1=Rarely, 2=Occasionally, 3=Frequently, 4=Almost constantly), or the symptom's interference with one's "usual or daily activities" (0=Not at all, 1=A little bit, 2=Somewhat, 3=Quite a bit, 4=Very much). The symptom row title will indicate "Severity", "Frequency", or "Interference". All scores are compared between arms; statistical analysis results are entered for p-values \< 0.05.
| Participants | SRT + Standard ADT | SRT + Enhanced ADT |
|---|---|---|
| Taste Changes Severity | 3 | 8 |
| Decreased Appetite Severity | 2 | 6 |
| Decreased Appetite Interference | 2 | 4 |
| Nausea Frequency | 8 | 8 |
| Nausea Severity | 7 | 3 |
| Constipation Severity | 13 | 9 |
| Loose Stool Frequency | 30 | 19 |
| Abdominal Pain Frequency | 19 | 14 |
| Abdominal Pain Severity | 13 | 9 |
| Abdominal Pain Interference | 10 | 7 |
| Bowel Movement Control Frequency | 9 | 5 |
| Bowel Movement Control Interference | 7 | 5 |
| Racing Heartbeat Frequency | 5 | 6 |
| Racing Heartbeat Severity | 3 | 1 |
| Itchy Skin Severity | 10 | 3 |
| Concentration Problems Severity | 9 | 11 |
| Concentration Problems Interference | 12 | 11 |
| Memory Problems Severity | 7 | 11 |
| Memory Problems Interference | 8 | 11 |
| Headache Frequency | 12 | 9 |
| Headache Severity | 5 | 9 |
| Headache Interference | 5 | 6 |
| Fatigue Severity | 29 | 31 |
| Fatigue Interference | 31 | 34 |
| Pain with Urination Severity | 4 | 6 |
| Urinary Urgency Frequency | 38 | 37 |
| Urinary Urgency Interference | 23 | 25 |
| Frequent Urination Frequency | 46 | 45 |
| Frequent Urination Interference | 25 | 24 |
| Urine Control Loss Frequency | 39 | 39 |
| Urine Control Loss Interference | 22 | 28 |
| Erection Difficulty Severity | 40 | 24 |
| Ejaculation Problems Frequency | 26 | 18 |
| Decreased Sexual Interest Severity | 42 | 33 |
| Breast Tenderness Severity | 7 | 7 |
| Hot Flashes Frequency | 56 | 63 |
| Hot Flashes Severity | 32 | 44 |
| Pain Frequency | 35 | 33 |
| Pain Severity | 21 | 23 |
| Pain Interference | 16 | 23 |
Progression-free survival (PFS) is estimated by the Kaplan-Meier method. PFS time is measured from randomization to the date of first PFS failure (biochemical or clinical failure, initiation of new unplanned anticancer treatment, or death from any cause) or last known follow-up (censored). Analysis was to occur after progression or death was reported for 101 participants. Biochemical failure is defined as first post-RT PSA ≥ 0.2. Clinical failure is defined as either a local, regional, or distant failure.
| percentage of participants | SRT + Standard ADT | SRT + Enhanced ADT |
|---|---|---|
| 1 year | 87.5 (83.2 to 91.8) | 91.9 (88.1 to 95.6) |
| 2 years | 78.8 (73.4 to 84.2) | 88.3 (83.8 to 92.7) |
Collected over Baseline to the date of last known follow-up. Maximum follow-up time was 40.1 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SRT + Standard ADT | 2/98 (2%) | 11/98 (11.2%) | 89/98 (90.8%) |
| SRT + Enhanced ADT | 0/90 (0%) | 17/89 (19.1%) | 87/89 (97.8%) |
| Event | SRT + Standard ADT | SRT + Enhanced ADT |
|---|---|---|
| HematuriaRenal and urinary disorders | 0/98 | 3/89 |
| Heart failureCardiac disorders | 1/98 | 2/89 |
| Lung infectionInfections and infestations | 0/98 | 2/89 |
| SepsisInfections and infestations | 1/98 | 2/89 |
| Acute kidney injuryRenal and urinary disorders | 0/98 | 2/89 |
| AnemiaBlood and lymphatic system disorders | 2/98 | 1/89 |
| LeukocytosisBlood and lymphatic system disorders | 0/98 | 1/89 |
| Atrial fibrillationCardiac disorders | 0/98 | 1/89 |
| Myocardial infarctionCardiac disorders | 1/98 | 1/89 |
| Eye disorders - OtherEye disorders | 0/98 | 1/89 |
| Event | SRT + Standard ADT | SRT + Enhanced ADT |
|---|---|---|
| Hot flashesVascular disorders | 72/98 | 73/89 |
| FatigueGeneral disorders | 70/98 | 65/89 |
| DiarrheaGastrointestinal disorders | 61/98 | 48/89 |
| Urinary incontinenceRenal and urinary disorders | 43/98 | 30/89 |
| Urinary frequencyRenal and urinary disorders | 39/98 | 35/89 |
| AnemiaBlood and lymphatic system disorders | 16/98 | 33/89 |
| Urinary urgencyRenal and urinary disorders | 36/98 | 25/89 |
| NauseaGastrointestinal disorders | 18/98 | 28/89 |
| HypertensionVascular disorders | 25/98 | 28/89 |
| ConstipationGastrointestinal disorders | 28/98 | 25/89 |
Randomized participants
| Age, Continuous(years) | SRT + Standard ADT | SRT + Enhanced ADT | Total |
|---|---|---|---|
| Median | 65 (48 to 78) | 63 (47 to 77) | 64 (47 to 78) |
| Sex: Female, Male(Participants) | SRT + Standard ADT | SRT + Enhanced ADT | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 98 | 90 | 188 |
| Ethnicity (NIH/OMB)(Participants) | SRT + Standard ADT | SRT + Enhanced ADT | Total |
|---|---|---|---|
| Hispanic or Latino | 8 | 4 | 12 |
| Not Hispanic or Latino | 89 | 82 | 171 |
| Unknown or Not Reported | 1 | 4 | 5 |
| Race (NIH/OMB)(Participants) | SRT + Standard ADT | SRT + Enhanced ADT | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 3 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 6 | 15 | 21 |
| White | 85 | 67 | 152 |
| More than one race | 2 | 3 | 5 |
| Unknown or Not Reported | 5 | 2 | 7 |
| Baseline PSA(ng/mL) | SRT + Standard ADT | SRT + Enhanced ADT | Total |
|---|---|---|---|
| Median | 0.565 (0.11 to 9.56) | 0.785 (0.109 to 24.8) | 0.605 (0.109 to 24.8) |
| Pathologic T-Stage(Participants) | SRT + Standard ADT | SRT + Enhanced ADT | Total |
|---|---|---|---|
| T2 | 21 | 15 | 36 |
| T3 | 2 | 2 | 4 |
| T3a | 31 | 28 | 59 |
| T3b | 42 | 43 | 85 |
| T4 | 2 | 2 | 4 |
| Pathologic N-Stage(Participants) | SRT + Standard ADT | SRT + Enhanced ADT | Total |
|---|---|---|---|
| N0 | 63 | 63 | 126 |
| N1 | 20 | 21 | 41 |
| NX | 15 | 6 | 21 |
| Gleason Score(Participants) | SRT + Standard ADT | SRT + Enhanced ADT | Total |
|---|---|---|---|
| 6 | 1 | 0 | 1 |
| 7 | 39 | 34 | 73 |
| 8 | 11 | 5 | 16 |
| 9 | 46 | 51 | 97 |
| 10 | 1 | 0 | 1 |
2 further baseline measures are reported on the registry.
Showing the first 100 of 108 sites across 2 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2019 to primary completion in Apr 2023, 47 months.
Results were first posted in Oct 2024, 1 year 6 months after primary completion.
Of 613 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's 47 months is below that.
Counting every sponsor, half of 727 studies reached it within 53 months; a quarter within 34 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Enzalutamide
RTOG Foundation, Inc.